As our population ages and outcomes from revascularization also improve, more elderly patients are being referred for coronary artery bypass graft surgery (CABG) and for percutaneous coronary intervention (PCI).
Angioedema is an infrequent, but serious, adverse event from drug therapy. Drugs that affect the renin-angiotensin-aldosterone system have been linked to angioedema, but the relative frequency of this complication with these drugs is poorly understood.
This paper details the result of a population-based cohort study of all Ontario, Canada, residents older than 66 years of age who began warfarin therapy for atrial fibrillation over an 11-year period.
This paper reviews drug therapy in patients with atrial fibrillation in the Medicare population. The author extracted a 5% sample of Medicare beneficiaries who were enrolled in Medicare Part D.
Percutaneous coronary intervention (PCI) is performed in more than 600,000 patients annually in the United States, and women make up approximately one-third of this population.
